ELVN
EnlivenยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
ELVN Profile
Enliven Therapeutics, Inc.
A clinical-stage biopharmaceutical company developing new therapies to treat rare inherited hemoglobin diseases and other serious diseases
6200 Lookout Road, Boulder, CO 80301
--
Enliven Therapeutics, Inc., was incorporated in Delaware in June 2019. Enliven is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule inhibitors that help cancer patients not only live longer, but live better. Enliven's goal is to address existing and emerging unmet needs through a precise oncology approach that improves survival and overall patient well-being. Enliven's discovery process combines insights from clinically validated biological targets and differentiated chemistry with the goal of designing best-in-class or best-in-class therapies. By combining clinically validated targets and specific target product profiles, or TPPs, with rigorous clinical trial design and regulatory strategies, Enliven aims to develop drugs that are more likely to achieve clinical and commercial success. Clinically validated targets refer to biological targets that have demonstrated statistically significant efficacy endpoints in published third-party clinical trials, and Enliven believes these targets support the development of its product candidates by increasing their probability of success. Enliven has assembled a team of experienced drug hunters with extensive expertise in the discovery and development of small molecule kinase inhibitors. Enliven's team includes more than 20 major or co-inventors of product candidates that have entered clinical trials, including four FDA-approved products: Koselugo (selumetinib), Mektovi (binimetinib), Tukysa (tucatinib) and Retevmo (selpercatinib).
